Cargando…

Attenuation of OX40 signaling suppression by age disrupts peripheral deletion of CD4(+) T cells specific for the epidermal autoantigen desmoglein 3

Various autoimmune responses increase with age, but the underlying mechanism is not clear. In this study, we used CD4(+) T cells expressing a transgenic T cell receptor specific for desmoglein 3 (Dsg3), which is the target antigen of the autoimmune bullous disease pemphigus vulgaris, to examine how...

Descripción completa

Detalles Bibliográficos
Autores principales: Iriki, Hisato, Mukai, Miho, Asahina, Yasuhiko, Kubo, Yoko, Ito, Hiromi, Amagai, Masayuki, Takahashi, Hayato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10259059/
https://www.ncbi.nlm.nih.gov/pubmed/37308897
http://dx.doi.org/10.1186/s12979-023-00353-9
Descripción
Sumario:Various autoimmune responses increase with age, but the underlying mechanism is not clear. In this study, we used CD4(+) T cells expressing a transgenic T cell receptor specific for desmoglein 3 (Dsg3), which is the target antigen of the autoimmune bullous disease pemphigus vulgaris, to examine how peripheral immunological tolerance against pathogenic autoreactive CD4(+) T cells changes with age. Dsg3-specific T cells were deleted within 14 days after adoptive transfer into young mice (8 weeks old), while they escaped deletion when transferred into older mice over 42 weeks old. Dsg3-specific T cells produced higher levels of the proinflammatory cytokine IFN-γ in aged mice than in young mice. In addition, the expression levels of both OX40 and Birc5, which are important for cell survival in T cell clonal proliferation, were higher in aged than in young mice. The dysfunction in suppressing proinflammatory cytokine secretion and Birc5 upregulation in Dsg3-specific autoreactive T cells may reflect an aspect of the preliminary steps in autoimmune disease development in the aged population. Understanding this mechanism may lead to better risk evaluation of autoimmune disease development and to onset prevention. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12979-023-00353-9.